StoryRegulatory
EMA rejects Elevidys; Roche plans new pivotal trial for European approval
The European Medicines Agency rejected conditional marketing authorisation for Elevidys, finding the 0.65-point improvement in the primary endpoint (North Star Ambulatory Assessment) insufficient despite positive secondary measures. Roche committed to launching a new global Phase III trial.